Anthropic expands AI drug development and acquires Mithril
AI summary
Anthropic detailed early-stage drug-development work with six partners and said it had acquired Mithril, a one-person company focused on muscular dystrophy. The company said AI could speed drug development beyond common uses such as proposing initial designs for new molecules. The announcement did not name the six partners or provide independent results from the work.
In-depth insight
Anthropic’s reported collaborations and acquisition add drug development and muscular-dystrophy research to its stated AI-for-science activities.
This source provides an excerpt. Continue reading on the original site.